Drug intelligence / Profile preview

ABD-007

Development stage: Preclinical
Lead developer: Abdera Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABD-007 is a preclinical radiopharmaceutical candidate being developed by Abdera Therapeutics. It is engineered using the company's proprietary Radio-Optimized Engineering (ROE) platform, which focuses on designing monoclonal antibodies with optimized pharmacokinetic profiles to deliver potent radioisotopes specifically to tumor cells while minimizing off-target toxicity. As of early 2024, the specific biological target for ABD-007 remains undisclosed. The asset is currently in the discovery phase, intended for the treatment of various cancers.

Beyond the preview

Go deeper on ABD-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABD-007.

Explore the full profile